Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus - 21/06/19
Abstract |
Nail involvement in psoriasis is common, and the severity of it does not always parallel the intensity of cutaneous disease. We created a consensus group, of which the aim was to provide practical recommendations for the treatment of nail psoriasis in patients without skin psoriasis or with mild skin lesions with no indication for a systemic treatment. This collaborative process was conducted by an international panel of dermatologists with special expertise in nail disorders, using formal consensus methods. During this process, the panel strived to establish an agreement regarding the definition of nail psoriasis, the severity of nail psoriasis, and treatment response. Treatment recommendations are provided regarding nail psoriasis severity and matrix or bed involvement. Few-nail disease was considered as nail psoriasis affecting ≤3 nails. In the case of matrix involvement only, intralesional steroid injections were considered the treatment of choice. Topical steroids alone or in combination with topical vitamin D analogues were suggested for nail psoriasis limited to the nail bed. For the systemic treatment of nail psoriasis acitretin, methotrexate, cyclosporine, small molecules, and biologics may be employed.
Le texte complet de cet article est disponible en PDF.Key words : consensus, guidelines, intralesional steroid injection, nail psoriasis, nail psoriasis recommendation, nail psoriasis treatment
Abbreviations used : AE, IL, NAPSI, N-NAIL, NPQ10, PsA, QoL
Plan
All authors equally contributed to this report. |
|
Funding sources: None. |
|
Conflicts of interest: Dr Rigopoulos was a speaker and received honoraria from Celgene, Novartis, Janssen, and Abbvie; was a consultant and received honoraria from Celgene, Novartis, Janssen, and Abbvie; is or was a principle investigator for Abbvie and Genesis Pharma. Dr Gregoriou was a speaker and received honoraria from Abbvie, Janssen, and Novartis. Dr Pasch was an advisory board member for and received honoraria from Amgen and Celgene; was a speaker and received honoraria from Pfizer; and received research funding for fundamental research from Janssen Pharmaceutics and Pfizer. Bianca Maria Piraccini was an advisory board member for Pierre fabre-Ducray, L'Oreal, Legacy Healthcare and has received honoraria from Pierre fabre-Ducray, L'Oreal, Legacy Healthcare, Giuliani, Avangarde, Canfield, and ISDIN. Dr Rich is or was a principle investigator for Abbvie, Boehringer Ingelheim, Cell Centix, Centocor, Eli Lilly, Janssen, Kadmon, Merck, Novartis, Pfizer, and UCB. Dr Rompoti was a speaker for and received honoraria from Janssen and Novartis. Dr Tosti was a consultant for and received honoraria from P&G and Amirall and is or was a principle investigator for Incyte, Nutrifol, and Erconia Laser. Drs Baran, Chiheb, Daniel, Chiacchio, Grover, Haneke, Iorizzo, Richert, Rubin, Starace, Singal, Triantafyllopoulou, and Zaiac have no conflicts of interest to declare. |
|
Reprints not available from the authors. |
Vol 81 - N° 1
P. 228-240 - juillet 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?